Watching RAPHAEL PHARMACEUTICAL INC.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planRAPHAEL PHARMACEUTICAL INC.
raphaelpharmaceutical.comAI Executive Summary
AI-powered analysis of 8-K filing content
Raphael Pharmaceutical Inc. announced the appointment of Uri Tadelis as Chief Financial Officer effective July 16, 2026, following the immediate resignation of Guy Ofir from the CFO, General Counsel, and Director positions. The company stated the departure was not due to disagreements, indicating a planned management transition.
Key Takeaways
Guy Ofir resigned from three positions (CFO, General Counsel, Director) effective immediately on July 16, 2026
Uri Tadelis was appointed as the new Chief Financial Officer on the same date
2 more takeaways
Filing Overview
What This Means
RAPHAEL PHARMACEUTICAL INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.